Gt biopharma reports fourth quarter and full-year 2021 financial results and provides corporate update

Presented novel trike® pre-clinical data driving nk cell immunotherapy against non-small cell lung cancer (nsclc) in the hypoxic solid tumor microenvironment at esmo tat congress. demonstrated novel b7-h3 targeting dual camelid nanobody trike® and gtb-5550 induce nk cell activation against broad spectrum of tumors at esmo io congress 2021.
GTBP Ratings Summary
GTBP Quant Ranking